WO2010073667A1 - 紫外線防止剤 - Google Patents
紫外線防止剤 Download PDFInfo
- Publication number
- WO2010073667A1 WO2010073667A1 PCT/JP2009/007191 JP2009007191W WO2010073667A1 WO 2010073667 A1 WO2010073667 A1 WO 2010073667A1 JP 2009007191 W JP2009007191 W JP 2009007191W WO 2010073667 A1 WO2010073667 A1 WO 2010073667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultraviolet rays
- composition
- ultraviolet
- phenoxyethanol
- reduced water
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
Definitions
- the present invention relates to an ultraviolet inhibitor comprising phenoxyethanol and / or reduced water. Moreover, this invention relates to the composition which has the ultraviolet-ray prevention effect containing the cosmetics which have the ultraviolet-ray prevention effect containing the said ultraviolet-ray prevention agent, and the said ultraviolet-ray prevention agent.
- the present invention also relates to a method for preventing ultraviolet rays comprising applying the cosmetic or administering the composition to a subject in need of prevention from ultraviolet rays.
- the present invention also relates to a method for inhibiting cell damage due to ultraviolet rays, comprising applying the cosmetic or administering the composition to a subject in need of prevention from ultraviolet rays.
- the present invention also relates to the use of phenoxyethanol and / or reduced water in the production of UV inhibitors, cosmetics having UV protection effects, or compositions having UV protection effects.
- Ultraviolet rays are electromagnetic waves with a wavelength of 100 to 400 nm emitted by the sun. Based on the length of the wavelength, long wavelength ultraviolet rays (400 to 315 nm, called UVA), medium wavelength ultraviolet rays (315 to 280 nm, UVB) And short-wavelength ultraviolet (280-100 nm, referred to as UVC). It is known that ultraviolet rays are more damaging to a living body as the wavelength is shorter, for example, are more cytotoxic due to peroxidation or genetic damage, and the longer the wavelength, the deeper the skin is affected. On the other hand, some of the mid-wavelength UVB and short-wavelength UVC are absorbed by the ozone layer in the atmosphere, and the UV that reaches the earth's surface is a long-wavelength UVA and a small amount of UVB.
- UVA long wavelength ultraviolet rays
- UVB medium wavelength ultraviolet rays
- UVC short-wavelength ultraviolet
- UV rays have an damaging effect on various organs such as the skin.
- inflammatory mediators produced by epidermal cells by the stimulation act on surrounding cells, resulting in erythema pigmentation.
- active oxygen is generated in cells in the skin, causing collagen fibers and elastic fibers to be cut and degenerated, causing wrinkles. It can also cause DNA damage and induce cancerous cells.
- eye diseases such as cataracts and age-related macular degeneration are said to be caused by ultraviolet rays.
- the Langerhans cells existing in the middle layer of the epidermis are irradiated with ultraviolet rays, the antigen-presenting function of the cells is lost, and interleukin 10 and the like are released from keratinocytes, thereby reducing the immune function of the whole body.
- Cosmetics such as sunscreens are used to prevent damage to cells and organs caused by ultraviolet rays.
- the main components contained in the sunscreen agent are an ultraviolet absorber and a scattering agent, and these are used alone or in combination. Both the absorbent and the scattering agent absorb or block ultraviolet rays to reduce the arrival of ultraviolet rays to skin cells, but their use is not sufficient to prevent damage to cells and organs caused by ultraviolet rays.
- drugs that prevent the damaging effect of ultraviolet rays on ocular tissues.
- An object of the present invention is to provide a drug and a method capable of preventing damage to cells and organs caused by ultraviolet rays.
- the present inventors have used a UV effect inspection system using cultured human cells, found that I & C active hydrogen cosmetics, and reduced water and phenoxyethanol, which are components of the cosmetics, reduce cell damage due to ultraviolet rays. Achieved.
- the present invention relates to an ultraviolet inhibitor comprising phenoxyethanol and / or reduced water.
- the present invention also relates to a cosmetic material having an ultraviolet ray preventing effect, comprising an ultraviolet ray inhibitor comprising phenoxyethanol and / or reduced water.
- the present invention provides that the cosmetic comprises 0.1 to 10% (v / v) phenoxyethanol and / or 0.1% to 99.9% (v / v) reduced water, wherein all ingredients contained in the cosmetic The total is 100% (v / v).
- the present invention relates to a composition having an anti-ultraviolet effect, comprising an anti-UV agent comprising phenoxyethanol and / or reduced water.
- the invention also provides that the composition comprises 0.1 to 10% (v / v) phenoxyethanol and / or 0.1% to 99.9% (v / v) reduced water, wherein all ingredients contained in the composition Relates to the composition, wherein the total is 100% (v / v).
- the present invention relates to any one of the above compositions, wherein the composition is an external composition for skin or an ophthalmic composition.
- the present invention relates to a method for preventing ultraviolet rays, which comprises applying a cosmetic containing an ultraviolet inhibitor comprising phenoxyethanol and / or reduced water to a subject that needs to be prevented from ultraviolet rays.
- the present invention also relates to a method for preventing ultraviolet rays, comprising administering a composition containing an ultraviolet inhibitor comprising phenoxyethanol and / or reduced water to a subject in need of prevention from ultraviolet rays.
- the present invention relates to the method for preventing ultraviolet rays, wherein the composition is a skin external preparation composition or an ophthalmic composition.
- the present invention relates to a method for inhibiting cell damage caused by ultraviolet rays, which comprises applying a cosmetic containing an ultraviolet ray inhibitor composed of phenoxyethanol and / or reduced water to a subject requiring prevention from ultraviolet rays.
- the present invention also relates to a method for inhibiting cytotoxicity caused by ultraviolet rays, comprising administering a composition containing an ultraviolet inhibitor comprising phenoxyethanol and / or reduced water to a subject in need of prevention from ultraviolet rays.
- the present invention relates to a method for inhibiting cell damage, wherein the cell damage is cell skin damage or eye tissue damage.
- the present invention relates to the use of phenoxyethanol and / or reduced water in the production of a UV-protecting agent, a cosmetic having an UV-blocking effect, or a composition having an UV-blocking effect.
- a UV inhibitor comprising phenoxyethanol and / or reduced water, a cosmetic having an UV preventive effect including the UV inhibitor, and a composition having an UV preventive effect including the UV inhibitor.
- This composition can be used, for example, as a skin external preparation or an ophthalmic preparation.
- a method for preventing ultraviolet rays including applying the cosmetic or administering the composition to a subject requiring prevention from ultraviolet rays.
- a method for inhibiting cell damage caused by ultraviolet rays which comprises applying the cosmetic or administering the composition to a subject that needs to be prevented from ultraviolet rays.
- the present invention relates to an anti-ultraviolet agent, a cosmetic having an anti-ultraviolet effect containing the anti-ultraviolet agent, and a composition having an anti-ultraviolet effect containing the anti-ultraviolet agent.
- the ultraviolet ray inhibitor according to the present invention is characterized by comprising phenoxyethanol and / or reduced water. Phenoxyethanol and reduced water can be used alone or in combination.
- UV protection agent means an agent that prevents the biological action of UV rays.
- the biological action of ultraviolet rays means the action of ultraviolet rays on living bodies, tissues and cells.
- the ultraviolet ray inhibitor according to the present invention has an action of reducing cytotoxic activity by ultraviolet rays, thereby preventing the biological action of ultraviolet rays.
- cultured human cells that respond with high sensitivity to the biological action of ultraviolet rays using phenoxyethanol, reduced water, and a cosmetic solution containing phenoxyethanol and reduced water (I & C active hydrogen cosmetic: manufactured by I & C Co., Ltd.) From the results of the MTT assay, the effects of ultraviolet irradiation on the cells were examined, and it was found that all of these have the effect of reducing the cytotoxic activity of ultraviolet rays.
- phenoxyethanol is added to 1/10 to 1/100 volume (v / v) and pretreated with the cultured cells, so that resistance to cytotoxicity due to ultraviolet irradiation is smaller than when no phenoxyethanol is added. Increased sex more than twice.
- reducing water is pretreated by adding 1/100 amount (v / v), and compared to the case without addition, the resistance to cytotoxicity due to ultraviolet irradiation is 1.2 to 1.3 times. Doubled.
- a cosmetic solution containing phenoxyethanol and reducing water is pretreated by adding 1/100% amount (v / v) of the cosmetic solution, so that it is more resistant to cell damage after UV irradiation than when it is not added.
- the main causes of the cytotoxic action of ultraviolet rays include direct action on nucleic acids such as DNA present in the cell nucleus and mitochondria, and activation of signal transduction pathways related to apoptosis. Phenoxyethanol and reduced water are each expected to act alone to reduce cell damage due to ultraviolet rays through either or both of these pathways. Furthermore, it can be considered that a product or cosmetic containing them as a composition component acts as a combined action of these composition components so as to reduce cell damage due to ultraviolet rays.
- Cytotoxic activity can also be referred to as a cytotoxic action, and means an action that causes cell damage. Damaged cells eventually lead to cell death. Therefore, the cytotoxic activity of ultraviolet rays is related to cell death and survival.
- the ultraviolet ray inhibitor according to the present invention has an action of reducing cytotoxic activity due to ultraviolet rays, and can reduce damage to living tissues and cells caused by exposure of the living body to ultraviolet rays, and thus cell death.
- ultraviolet ray preventing agent means a drug having an action of reducing the cytotoxic activity of ultraviolet rays, and more specifically, damage to living tissues and cells caused by exposure of the living body to ultraviolet rays, Means an agent that reduces cell death.
- the ultraviolet ray inhibitor can be used as an agent for preventing cell damage due to ultraviolet rays.
- the “ultraviolet ray prevention effect” means an effect of reducing the cytotoxic activity of ultraviolet rays, that is, an effect of reducing the damage of biological tissues and their cells caused by the biological action of ultraviolet rays, and hence cell death.
- Phenoxyethanol is a kind of glycol ether and is known to have bactericidal action against Gram-negative bacteria such as Pseudomonas aeruginosa. Since phenoxyethanol has a bactericidal action, it is used as a preservative, antibacterial preservative, disinfectant and the like in the fields of perfume and cosmetics. Moreover, phenoxyethanol is used as a solvent for various chemicals. Phenoxyethanol can use a commercial product.
- the dose of phenoxyethanol is 0.01 to 10% (v / v), preferably 0.1 to 10% (v / v), more preferably 0.1 to 1% (v / v), and even more preferably 1 %.
- the use of phenoxyethanol is set within 1 g per 100 g of product according to cosmetic standards. Since the specific gravity of phenoxyethanol is about 1.109, when water is used as a solvent, it is preferably used at a dose of about 0.9% (v / v) or less.
- Reduced water means water exhibiting a negative redox potential.
- the negative oxidation-reduction potential is also called a reduction potential, and means a negative potential at a potential generated when electrons are exchanged in a certain oxidation-reduction reaction system, that is, an oxidation-reduction potential, and indicates ease of electron emission.
- the reduced water used in the present invention can be any water as long as it exhibits a negative potential of 0 mV or more, preferably -50 mV or more, more preferably -100 mV or more, more preferably -150 mV or more, even more. Water showing a negative potential of preferably ⁇ 200 mV or more, more preferably ⁇ 250 mV or more is suitable.
- the redox potential of a solution such as water can be measured simply using a commercially available redox potential meter.
- the reduced water may be any water as long as it has a negative oxidation-reduction potential, and is water called active hydrogen water, electrolytic reduction water, alkaline reduction water, etc., and has a negative oxidation-reduction potential. including.
- As the reduced water both natural reduced water and produced reduced water can be used. Natural reduced water is spring water or well water that has a negative redox potential.
- Various methods for producing reduced water have been reported. For example, a method for increasing dissolved hydrogen by electrolyzing water is known. The reduced water can be easily produced using a known water electrolysis method and an apparatus using the method. Specific examples of the produced reduced water include Hayakawa mineral reduced water produced using the method and apparatus developed and reported by Hideo Hayakawa et al. (Patent Documents 1 to 3).
- the dose of reduced water is 0.1% to 100% (v / v), preferably 1% to 100%.
- the ultraviolet ray prevention agent according to the present invention is preferably an ultraviolet ray prevention agent for skin tissue or eye tissue because the biological sites that are susceptible to the biological action of ultraviolet rays are skin tissue and eye tissue.
- Skin tissue refers to a tissue constituting the skin of the head, trunk, and extremities of a living body.
- the skin tissue is composed of three layers of epidermis, dermis and subcutaneous fat tissue, and hair follicles, sebaceous glands, sweat glands and the like differentiated from the epidermis.
- Skin tissue cells refers to cells that are present in skin tissue, and are keratinocytes, granule cells, spine cells, basal cells, Langerhans cells, and melanocytes, fibroblasts contained in the dermis, macrophages contained in the epidermis. And mast cells, plasma cells, and hair matrix cells.
- Opt tissue means surrounding tissues including the eyeball, and from structures with different structures such as eyelid, conjunctiva, cornea, iris, ciliary body, lens, vitreous, retina, choroid, sclera, optic nerve, orbital tissue It is configured.
- Eye tissue cells refers to cells present in ocular tissues, and examples include conjunctival cells, corneal cells, iris cells, lens cells, and retinal cells.
- the ultraviolet ray inhibitor according to the present invention can be used as an active ingredient of a composition having an ultraviolet ray preventing effect. That is, in this invention, the composition which has the ultraviolet-ray prevention effect which contains the ultraviolet-ray inhibitor which concerns on this invention as an active ingredient, and its effective amount can be provided. More specifically, it is possible to provide a composition having an anti-ultraviolet effect comprising an effective amount of phenoxyethanol and / or reduced water as an active ingredient that reduces the cytotoxic activity of ultraviolet rays.
- the phenoxyethanol contained in the composition according to the present invention is 0.01 to 10% (v / v), preferably 0.1 to 10% when the total of all components contained in the composition is 100% (v / v). % (V / v), more preferably 0.1 to 1% (v / v), still more preferably 1%.
- the reduced water contained in the composition is 0.1% to 99.9% (v / v), preferably 1% when the total of all the components contained in the composition is 100% (v / v). ⁇ 99.9% (v / v). More preferably, the composition according to the present invention contains phenoxyethanol and reduced water, and the content thereof is 0.1% when the total of all components contained in the composition is 100% (v / v). ⁇ 10% (v / v) and 0.1% ⁇ 99.9% (v / v).
- the composition having the effect of preventing ultraviolet rays according to the present invention is preferably used as an external preparation for skin because the site susceptible to the biological action of ultraviolet rays is skin tissue.
- the topical skin preparation according to the present invention is characterized by containing phenoxyethanol and / or reduced water as an active ingredient that lowers the cytotoxic activity of ultraviolet rays, so that skin tissue, hair, etc. Can protect against injury caused by action.
- “External skin preparation” means cosmetics, pharmaceuticals, and quasi drugs applied to the skin. These dosage forms are arbitrary, and may be any form such as a solution, solid, suspension, fat emulsion, ointment, cream, foam, gel, etc. Examples of dosage forms used for pharmaceuticals, quasi drugs, and the like, such as lotions, emulsions, packs, foundations, creams, ointments, gels, and the like.
- composition having the effect of preventing ultraviolet rays according to the present invention is preferably used as a cosmetic.
- Cosmetic means “a composition for treating the human body for the purpose of beautification, cleanliness, protection, or deodorization.
- the cosmetic is applied to the head, face, trunk, and extremities.
- the cosmetics may be in any form of liquid cosmetics and solid cosmetics, and the type of application is not particularly limited as long as it is a form normally used in cosmetics. Examples include basic cosmetics such as emulsions, creams and packs, under makeup cosmetics, foundations, lip colors, makeup cosmetics such as lip balms, and hair cosmetics such as hair lotions and hair creams.
- the external preparation for skin can contain optional components usually used in cosmetics, pharmaceuticals and quasi drugs in addition to the ultraviolet light inhibitor according to the present invention.
- optional ingredients include hydrocarbons such as squalane, petrolatum and microcrystalline wax, esters such as jojoba oil, carnauba wax, olein sanoctyldodecyl, triglycerides such as olive oil and coconut oil, myristic acid, stearin Examples thereof include fatty acids such as acid, oleic acid and lauric acid, higher alcohols such as oleyl alcohol, stearyl alcohol and octyldodecanol, and polyhydric alcohols such as polyethylene glycol, glycerin and 1,3-butanediol.
- a thickener such as hydroxypropylcellulose or hydroxymethylcellulose, volatilization of phenoxyethanol, which is low in volatility but volatile, can be suppressed. Therefore, it is preferable to include such a thickener.
- Skin external preparations include skin care ingredients such as whitening ingredients, moisturizing ingredients, wrinkle formation inhibiting ingredients, and skin nutrients used as ingredients in cosmetics, pharmaceuticals and quasi-drugs, in addition to the ultraviolet light inhibitor according to the present invention.
- Anti-inflammatory agents, antioxidants, cell activators and the like can be included.
- the compound which has an ultraviolet-ray prevention effect other than phenoxyethanol and reduced water can be contained.
- composition having an ultraviolet ray preventing effect according to the present invention is preferably used as an ophthalmic preparation because a site susceptible to the biological action of ultraviolet rays is ocular tissue.
- the ophthalmic preparation according to the present invention is characterized by containing phenoxyethanol and / or reduced water as an effective component for reducing the cytotoxic activity of ultraviolet rays. Can be protected.
- Ophthalmic preparation means a preparation that is administered to the eye in an ophthalmic disease, and is classified into an ophthalmic solution and an ointment. Ophthalmic solutions are classified as eye drops and eye wash. An eye drop means a preparation prepared by aseptically producing a pharmaceutical solution or suspension and administered to the eye.
- the ophthalmic preparation can contain optional components usually used in ophthalmic preparations, in addition to the ultraviolet light inhibitor according to the present invention.
- optional components include pharmaceutical carriers such as stabilizers, thickeners, isotonic agents, solubilizers, antioxidants, and buffers.
- the stabilizer include edetic acid and sodium edetate.
- the thickener include cellulose polymer compounds such as methyl cellulose and hydroxypropyl methyl cellulose, polyvinyl polymer compounds such as polyvinyl pyrrolidone and polyvinyl alcohol, liquid paraffin, and polyethylene glycol.
- the isotonic agent include potassium chloride, sodium chloride, glycerin and the like.
- solubilizers include polyhydric alcohols such as propylene glycol, polyethylene glycol, and sorbitol, polysorbate 80, and POE sorbitan fatty acid esters such as monoolein sun POE (20) sorbitan.
- antioxidant include dibutylhydroxytoluene, hydroquinone, sodium bisulfite and the like.
- Buffering agents include boron-based buffers such as boric acid, acetic acid-based buffers such as sodium acetate and potassium acetate, phosphate-based buffers such as sodium hydrogen phosphate and potassium dihydrogen phosphate, and carbonates such as sodium carbonate.
- the buffer include citrate buffers such as buffer, citric acid and sodium citrate. These are used singly or in combination of two or more.
- the ophthalmic preparation can also contain drugs for eye diseases, such as decongestants, ocular muscle modifiers, cataract treatment ingredients, and refreshing agents and vitamins commonly used in ophthalmic preparations.
- drugs for eye diseases such as decongestants, ocular muscle modifiers, cataract treatment ingredients, and refreshing agents and vitamins commonly used in ophthalmic preparations.
- the anti-ultraviolet agent and the anti-UV composition according to the present invention are produced using phenoxyethanol and / or reduced water as an active ingredient that reduces the cytotoxic activity of ultraviolet rays. It has the effect of reducing cell and tissue damage caused by the action. Therefore, the use of the present drug and composition can prevent or reduce the occurrence of skin damage caused by ultraviolet rays and the occurrence or exacerbation of eye diseases caused by ultraviolet rays.
- Skin damage caused by ultraviolet rays includes sunburn such as sun dermatitis and post-inflammation pigmentation, senile pigment spots, photoaging such as solar elasticity fibrosis and senile warts, and basal cell carcinoma, squamous cell carcinoma and malignant melanoma Examples are skin cancer.
- Examples of eye diseases that are caused or exacerbated by ultraviolet rays include inflammation of the cornea and conjunctiva such as light-induced keratitis and pterygium, cataracts, and age-related macular degeneration.
- the ultraviolet ray preventing agent and the composition having an ultraviolet ray preventing effect according to the present invention can be used to prevent ultraviolet rays, that is, to prevent cell damage due to ultraviolet rays. That is, the present invention can provide a method for preventing ultraviolet rays and a method for inhibiting cell damage caused by ultraviolet rays. This ultraviolet ray prevention method and the method for inhibiting cell damage by ultraviolet ray can be carried out by administering the ultraviolet ray preventing agent or the composition having an ultraviolet ray preventing effect to a subject in need of protection from ultraviolet ray.
- the administration route can be selected from systemic administration or local administration.
- an appropriate administration route is selected according to the disease, symptoms and the like.
- parenteral routes include normal intravenous administration, intraarterial administration, subcutaneous, intradermal, intramuscular administration, and the like.
- it can be administered by the oral route.
- transmucosal administration or transdermal administration is also possible.
- the administration form can be selected from various forms according to the purpose. Typical examples include aqueous solution preparations, ethanol solution preparations, suspensions, fat emulsions, liposome preparations, inclusions such as cyclodextrins, liquid dosage forms such as syrups and elixirs, tablets, pills, powders, Solid dosage forms such as powders, fine granules, granules, capsules and the like are included. Depending on the route of administration, these may be oral, parenteral (instillation, injection), nasal, inhalation, vaginal, suppository, sublingual, eye drops, ear drops, ointments, creams And can be prepared, molded and prepared according to ordinary methods.
- the ultraviolet prevention method according to the present invention is preferably applied to the prevention of ultraviolet rays in the skin or eyes.
- the ultraviolet ray inhibitor according to the present invention When the skin is prevented from being damaged by ultraviolet rays by the ultraviolet ray prevention method according to the present invention, it is preferable to directly apply the ultraviolet ray inhibitor according to the present invention or the composition having an ultraviolet ray preventing effect to the skin.
- Administration of the present drug or composition to the skin can be performed by applying or spraying the drug or composition to the skin in the form of an external preparation for skin such as cosmetics.
- the ultraviolet ray inhibitor according to the present invention When the eye part is prevented from being damaged by ultraviolet rays by the ultraviolet ray prevention method according to the present invention, it is preferable to directly apply the ultraviolet ray inhibitor according to the present invention or a composition having an ultraviolet ray preventing effect to the eye tissue.
- Administration of drugs or compositions to ocular tissues can be performed by administering them in the form of ophthalmic preparations.
- 1,3-butylene glycol obtained by adding methylparaben and ethylparaben, propylene glycol (trade name: Adeka PG, manufactured by Asahi Denka Kogyo Co., Ltd.), and Hisolv EPH to heating water are sequentially added and mixed. When the temperature reached 80 ° C., the heating was terminated. Cooling of the mixed solution was started 20 minutes after the completion of heating, and when it was cooled to 50 ° C., a fragrance (manufactured by Dragoco) was added, then pH was adjusted with citric acid and sodium citrate, and further cooled to 40 ° C.
- Adeka PG manufactured by Asahi Denka Kogyo Co., Ltd.
- RS cells are cultured human cells, and are easily damaged by ultraviolet (UVC) irradiation, and are therefore cells that can easily determine ultraviolet energy biological action (Non-patent Document 1).
- MTT (3- (4,5-dimethylthiazol-2yl) -2,5-diphenyltetrazolium bromide) is cleaved into formazan by the release of reductase that exists in mitochondria and is involved in cell respiration. Is a method for evaluating cytotoxicity by colorimetric determination of the produced formazan dye.
- the cells cultured with the cosmetic solution added showed higher resistance to UV-induced cell damage than the cells cultured without the cosmetic solution added (FIG. 1).
- Cell damage by ultraviolet light is in turn related to cell death and survival. That is, it can be considered that this cosmetic liquid reduces cell damage due to ultraviolet rays and thus prevents cell death due to ultraviolet rays.
- Cells cultured with reducing water added showed higher resistance to UV-induced cell damage than cells cultured without reducing water (FIG. 2).
- cells cultured with EPH added showed higher resistance to UV-induced cytotoxicity than cells cultured without EPH (FIG. 2).
- Cell damage by ultraviolet light is in turn related to cell death and survival. That is, it can be considered that reduced water reduces cell damage due to ultraviolet rays, and thus prevents cell death due to ultraviolet rays.
- both the I & C active hydrogen cosmetic manufactured by I & C Co., Ltd.
- the reduced water and EPH composing the cosmetic increased the resistance of the cells to cell damage caused by ultraviolet rays.
- I & C active hydrogen cosmetics manufactured by I & C Co., Ltd.
- UV irradiation The resistance to subsequent cell damage was increased from 1.2 times to about 4 times.
- the present invention provides a previously unknown use of phenoxyethanol and / or reduced water, and is extremely useful in the cosmetics and pharmaceutical fields.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化粧品液を1/100量(v/v)添加した細胞培養液中で細胞を1日間培養した後、紫外線で細胞を照射し、その3日後に細胞傷害の程度を測定した。比較対象として、該化粧品液を添加せずに同様に培養して紫外線照射による細胞傷害の程度を測定した。紫外線照射は4.5J/m2、10J/m2、および14J/m2の線量で実施した。
還元水またはEPHを添加した細胞培養液中で細胞を1日間培養した後、紫外線で細胞を照射し、その3日後に細胞傷害の程度を測定した。比較対象として、還元水およびEPHを添加せずに同様に培養して紫外線照射による細胞傷害の程度を測定した。還元水は1/100量(v/v)細胞培養液中に添加した。EPHは1/10量(v/v)または1/100量(v/v)細胞培養液中に添加した。紫外線照射は14J/m2の線量で実施した。
Claims (16)
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む、紫外線防止効果を有する化粧料。
- 化粧料が0.1~10%(v/v)のフェノキシエタノールおよび/または0.1%~99.9%(v/v)の還元水を含み、ここで該化粧料に含まれる全ての成分の合計が100%(v/v)である請求項2に記載の化粧料。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む、紫外線防止効果を有する組成物。
- 組成物が0.1~10%(v/v)のフェノキシエタノールおよび/または0.1%~99.9%(v/v)の還元水を含み、ここで該組成物に含まれる全ての成分の合計が100%(v/v)である請求項4に記載の組成物。
- 組成物が、皮膚外用組成物である請求項4または5に記載の組成物。
- 組成物が、眼科用組成物である請求項4または5に記載の組成物。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む化粧料を、紫外線からの防止を必要とする対象に適用することを含む紫外線防止方法。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む組成物を、紫外線からの防止を必要とする対象に投与することを含む紫外線防止方法。
- 前記組成物が、皮膚外用剤組成物である請求項9に記載の紫外線防止方法。
- 前記組成物が、眼科用組成物である請求項9に記載の紫外線防止方法。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む化粧料を、紫外線からの防止を必要とする対象に適用することを含む、紫外線による細胞傷害の防止方法。
- フェノキシエタノールおよび/または還元水からなる紫外線防止剤を含む組成物を、紫外線からの防止を必要とする対象に投与することを含む、紫外線による細胞傷害の阻害方法。
- 前記細胞傷害が皮膚組織における細胞傷害である、請求項13に記載の紫外線による細胞傷害の阻害方法。
- 前記細胞傷害が眼組織における細胞傷害である、請求項13に記載の紫外線による細胞傷害の阻害方法。
- 紫外線防止剤、紫外線防止効果を有する化粧料、または紫外線防止効果を有する組成物の製造におけるフェノキシエタノールおよび/または還元水の使用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010543885A JP5680420B2 (ja) | 2008-12-24 | 2009-12-24 | 紫外線防止剤 |
KR1020117017062A KR101723249B1 (ko) | 2008-12-24 | 2009-12-24 | 자외선 방지제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008327931 | 2008-12-24 | ||
JP2008-327931 | 2008-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010073667A1 true WO2010073667A1 (ja) | 2010-07-01 |
Family
ID=42287309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/007191 WO2010073667A1 (ja) | 2008-12-24 | 2009-12-24 | 紫外線防止剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5680420B2 (ja) |
KR (1) | KR101723249B1 (ja) |
WO (1) | WO2010073667A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004091439A (ja) * | 2002-09-04 | 2004-03-25 | Itaru Yamamoto | 日焼け予防用の皮膚外用剤 |
DE10355717A1 (de) * | 2003-11-26 | 2005-06-23 | Beiersdorf Ag | Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin mit gesteuerter Wasseraktivität |
JP2006056790A (ja) * | 2004-08-18 | 2006-03-02 | Pola Chem Ind Inc | 紫外線防護に好適な皮膚外用剤 |
WO2006094027A2 (en) * | 2005-03-02 | 2006-09-08 | Nascent Pharmaceutical, Inc. | Combination therapy for topical application |
JP2007045772A (ja) * | 2005-08-11 | 2007-02-22 | Pola Chem Ind Inc | 夏用の化粧料 |
JP2007217361A (ja) * | 2006-02-17 | 2007-08-30 | Shiseido Co Ltd | 化粧料組成物 |
JP2007302647A (ja) * | 2006-05-12 | 2007-11-22 | Daito Kasei Kogyo Kk | 化粧料 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06145036A (ja) * | 1992-11-05 | 1994-05-24 | Tokai Sangyo Kk | 紫外線防止化粧品組成物及びその製造方法 |
JP4390125B2 (ja) * | 2001-05-25 | 2009-12-24 | 昌治 久保田 | 還元水を用いた化粧水または化粧品 |
JP2003335654A (ja) * | 2002-05-15 | 2003-11-25 | Marvesala Kenkyusho:Kk | 化粧品及びその製造方法 |
JP2005232015A (ja) * | 2004-02-17 | 2005-09-02 | Shoji Kubota | 酸性の還元水を用いた化粧水または化粧品 |
JP2006008631A (ja) * | 2004-06-29 | 2006-01-12 | Yv Corporation:Kk | 化粧品 |
JP2006069974A (ja) * | 2004-09-03 | 2006-03-16 | Shoji Kubota | 弱酸性のミネラル濃縮液を原料水とする化粧水または化粧品 |
JP4968889B2 (ja) * | 2006-08-22 | 2012-07-04 | 株式会社 資生堂 | 皮膚外用組成物 |
JP2008069075A (ja) * | 2006-09-12 | 2008-03-27 | Kracie Home Products Kk | 皮膚外用組成物 |
JP4732307B2 (ja) * | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
JP2008195676A (ja) * | 2007-02-15 | 2008-08-28 | Noevir Co Ltd | 透明化粧料 |
-
2009
- 2009-12-24 KR KR1020117017062A patent/KR101723249B1/ko active IP Right Grant
- 2009-12-24 JP JP2010543885A patent/JP5680420B2/ja active Active
- 2009-12-24 WO PCT/JP2009/007191 patent/WO2010073667A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004091439A (ja) * | 2002-09-04 | 2004-03-25 | Itaru Yamamoto | 日焼け予防用の皮膚外用剤 |
DE10355717A1 (de) * | 2003-11-26 | 2005-06-23 | Beiersdorf Ag | Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin mit gesteuerter Wasseraktivität |
JP2006056790A (ja) * | 2004-08-18 | 2006-03-02 | Pola Chem Ind Inc | 紫外線防護に好適な皮膚外用剤 |
WO2006094027A2 (en) * | 2005-03-02 | 2006-09-08 | Nascent Pharmaceutical, Inc. | Combination therapy for topical application |
JP2007045772A (ja) * | 2005-08-11 | 2007-02-22 | Pola Chem Ind Inc | 夏用の化粧料 |
JP2007217361A (ja) * | 2006-02-17 | 2007-08-30 | Shiseido Co Ltd | 化粧料組成物 |
JP2007302647A (ja) * | 2006-05-12 | 2007-11-22 | Daito Kasei Kogyo Kk | 化粧料 |
Non-Patent Citations (1)
Title |
---|
MARI HARAMOTO ET AL.: "Denkai Kangensui (Bunshi Shukai Nano Setsudansui) ni yoru Bio Kosankazai no Kassei Zokyo Koka Oyobi Minus Ion Bihada Koka eno Hattensei", BIO INDUSTRY, vol. 20, no. 5, 2003, pages 58 - 64 * |
Also Published As
Publication number | Publication date |
---|---|
KR101723249B1 (ko) | 2017-04-04 |
JPWO2010073667A1 (ja) | 2012-06-07 |
JP5680420B2 (ja) | 2015-03-04 |
KR20110126596A (ko) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2756758C2 (ru) | Офтальмологические композиции | |
CA2742973C (en) | Use of low dosages of lipoic acid in the treatment of ocular disorders | |
EP3352766B1 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
JP2011500597A (ja) | 皮膚病又は皮膚病変の治療方法及び組成物 | |
KR20130101549A (ko) | 브리모니딘 겔 조성물 및 사용 방법 | |
JP2986432B2 (ja) | 非常に少ない用量のメラトニンまたはその類似体を含有する新規局所組成物およびその化粧品における使用 | |
JPH0826967A (ja) | クロロゲン酸又はその誘導体含有化粧料 | |
JP5680420B2 (ja) | 紫外線防止剤 | |
CN105726351B (zh) | 降低紫外线引起的脂质过氧化的协同组合物、制剂及相关方法 | |
RU2660359C2 (ru) | Косметические или дерматологические композиции, комбинирующие ретинальдегид и глицилглицин олеамид, и их косметические или дерматологические применения | |
US20190388321A1 (en) | Methods of treating hyperpigmentation disorders | |
KR20210093174A (ko) | 콜히친을 포함하는 피부 질환 치료용 조성물 | |
ES2716028T3 (es) | El uso de un extracto celular fotosintético que comprende tilacoides funcionales en composiciones cosméticas | |
KR102235063B1 (ko) | 청금석 또는 남동석 분말을 유효성분으로 포함하는 블루 라이트 차단용 화장료 조성물 | |
US20180280343A1 (en) | Topical silibinin formulations and uses therefor | |
JP2006117552A (ja) | 光老化防止用皮膚外用剤 | |
JP2007500173A (ja) | Uvb放射から皮膚を保護するためのビグアニド誘導体の使用 | |
KR102047193B1 (ko) | 글루타밀아미도에틸인돌을 활성 성분으로 포함하는 피부 트러블 개선용 외용제 조성물 및 광역학적 치료 조성물 | |
US8278289B2 (en) | Boroxine composition for removal of skin changes | |
KR102084415B1 (ko) | 에피피노레시놀을 포함하는 화장료 조성물 | |
EP4268827A1 (en) | Pharmaceutical composition for topical administration containing epinastine or salt thereof | |
TONE et al. | Acute local irritative effect of (2R)-4'-O-tetrahydropyranyladriamycin, a new antitumor antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09834473 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010543885 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117017062 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09834473 Country of ref document: EP Kind code of ref document: A1 |